Brain PET/MRI with Antibody-Based Tracers: A Quantitative and Kinetic Modeling Perspective
Webinar Overview
Antibody-based PET/MRI combines highly specific molecular imaging with detailed brain anatomy, enabling more accurate diagnosis, patient stratification, and treatment monitoring in neurological diseases. Its clinical application is currently limited by the challenge of delivering antibodies across the blood–brain barrier.
The webinar will provide an overview of the latest advances in antibody-based PET/MRI for brain imaging, with a particular focus on quantitative imaging and kinetic modelling. The session will discuss the development of novel antibody-based tracers, strategies to overcome the blood-brain barrier, and their applications in neuro-oncology and neurodegenerative diseases. Emphasis will be placed on the added value of quantitative PET biomarkers for understanding the kinetics of antibody-based radiotracers and characterizing target expression in vivo.
Thursday, October 1 2026
16:00 CEST
Key Learning Points
- Antibody-based PET/MRI for brain imaging
- Neuro-oncology and neurodegenerative diseases
- Quantitative imaging and kinetic modelling
Who Should Attend
This webinar is of interest to researchers working in neuro-oncology, neurodegenerative diseases, and brain-targeted drug development who use medical imaging techniques. It will be particularly relevant for those interested in quantitative PET biomarkers, kinetic modeling, antibody-based imaging, and the role of PET/MRI in characterizing biological processes and target expression in vivo.
What to expect
An overview of quantitative PET imaging and kinetic modelling for antibody-based PET/MRI in neuro applications